Compositions and Methods for the Treatment of Metabolic and Related Disorders
AssigneeBaylor College of Medicine
InventorsMotonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Mizuki Watanabe
Life of this patent
Estimating the term…
Abstract
The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.
Claims19
A compound having the chemical structure:
- A-B-C
- wherein A is a pyridine or a substituted pyridine, a piperidine or a substituted piperidine, a thiazole or a substituted thiazole, a benzimidazole or a substituted benzimidazole, a phenyl ring or a substituted phenyl ring;
- B is a thioazole or a substituted thioazole, a piperazine or a substituted piperazine, a triazolopyridine or a substituted triazolopyridine, a phenyl ring or a substituted phenyl ring or wherein A and B together are a benzothiazole or a substituted benzothiazole;
- and
- C is a phenyl ring or a substituted phenyl ring, a pyridine or a substituted pyridine, or a thioazole or a substituted thioazole.
A compound that is:
- 1 tert-butyl 3-(4-(4-bromophenyl)thiazol-2-yl)piperidine-1-carboxylate,
- benzyl-3-(4-(4-bromophenyl)thiazol-2-yl)piperidine-1-carboxylate,
- 3-(4-(4-bromophenyl)thiazol-2-yl)-1-propylpiperidine,
- benzyl-4-(4-(4-bromophenyl)thiazol-2-yl)piperidine-1-carboxylate,
- benzyl-3-(4-(4-(methylsulfonamido)phenyl)thiazol-2-yl)piperidine-1-carboxylate
- benzyl-4-(4-(4-(methylsulfonamido)phenyl)thiazol-2-yl)piperidine-1-carboxylate
- N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide,
- 4-(3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N-tosylbenzenamine,
- (4-(5-chloro-2-methylphenyl)piperazin-1-yl)(4-tosylamino)phenyl) methanone,
- 4-(4-((1-methyl-1H-benzo[d]imidazole-2-yl)methyl)piperazin-1-yl)-N-tosyl benzenamine,
- 3-chloro-4-methyl-N-(6-(4-(3-(trifluoromethyl)benzyl)piperazin-1-yl)pyridin-3-yl) benzenesulfonamide
- 4-chloro-N-(4-(4-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)piperazin-1-yl) phenyl)benzenesulfonamide
- (Z)-4-(3-cyano-3-(4-(2,4-dimethylphenyl)thiazol-2-yl)allyl)-N-(thiazol-2-yl)benzenesulfonamide
- N-(3-(H-imidazo[1,2-a]pyridine-2-yl)phenyl)-4-methyl-2-phenylthiazole-5-carboxamide,
- N-(3-(benzo[d]thiazol-2-yl)phenyl)isonicotinamide,
- 3-(4-chlorophenyl)-4,5-dihydro-1-phenyl-5-(2-phenylthiazol-4-yl)-1H-pyrazole,
- N-(4-(6-methylbenzo[d]thiazol-2-yl)phenyl)-2-(N-m-tolylmethylsulfonamido) acetamide;
- or
- N-(4-(6-methylbenzo[d]thiazol-2-yl)phenyl)-2-(N-p-tolylmethylsulfonamido) acetamide.
Dependencies are inferred from the claim text.